Everything drug pricing and policy, every day
Plus two academic papers worth reading, one raising concerns about step therapy and one raising concerns about MFN. Lots to be concerned about today!
And two links on PBMs, two on obesity, and a study that shows that cost-related nonadherence is on the wane
Plus a look at an IQVIA deep dive into a way of ensuring that 340B discounts make it directly to patients: ‘340 cards’
And looking through a fresh batch of comments on CMS IRA guidance makes clear that 340B is the elephant in the room
And the reconciliation bill is headed to a Senate vote today ... but without PBM reform or orphan-drug provisions
And IQVIA data shows the extent of the utilization management headaches for Medicare patients
And introducing a new way of segmenting the voices in the 340B debate: the (Jimmy) Buffett Rule
And the remarkable ability of hospitals to drive policy conversations in the Medicaid/reconciliation debate
And a veritable deluge of data about benefit design has me thinking about the impact on PBMs ... and patients
